Who are we?

Xcube.bio story

Our times are incredible times of biopharma innovation. Undrugable targets become drugable. New therapeutic modalities emerge. Expectations change for many hopeless patients with difficult-to-treat diseases. It takes thousands of agile, nimble and focused biopharma organizations to lead the development of thousands of promising therapeutics.

How are all these innovative drugs going to reach patients? Go-to-market options largerly remain the same. Innovators sell or license to a large pharmaceutical organization or take the risky and lonely bet to morph a R&D organization into a commercial powerhouse.

Xcube.bio was founded on the ground that go-to-market options must evolve, being also more agile, nimble and focused. Ultimately, we aim to connect efficiently each therapeutic innovation with any patient in need.
We strongly believe innovators ambition to get a direct access to their patients should not stop short of commercial hurdles. Through a unique blend of hands-on advisory, technology and financial engineering, xcube.bio offers an incubator-like approach unlocking innovator commercial journey. We are committed to delivering the innovator’s ecosystem to overcome knowledge, organizational and financial barriers at commercial stage.

#buildtogether, #jointhecube

Founder stories

Pierre-Henri (PH) Belin story

Pierre-Henri (PH) is co-founder and CEO of xcube.bio building on over 20 year of biopharmaceutical experience at Janssen, Actelion, OrthoBiotech and Virbac.
Soon in his career, PH found appetite for complex commercial and strategic operations. He led high-profile launches, affiliates building, business and country turnarounds, acquisition/integration.
PH greatest achievements happened in high-stake/high-stress projects, like closing the $30b acquisition of Actelion by Janssen and delivering the integration of its commercial operations across the globe.
PH’s background is at the crossroad of science, medicine and business, and his professional aspiration is based on the same tryptic: contribute to make scientific innovations meet patient needs and deliver business rewards. In this context, PH was blessed to lead many successful innovative drugs launches in HIV, HepC, Hematology and rare diseases in multiple markets and continents.
PH witnessed the fantastic science happening now in emerging Biopharma. He also witnessed the challenge of biopharma innovators to meet their patients and ultimately being rewarded by business. He co-founded xcube.bio, not as another pharma company or consultancy but as platform to find the way to patients across the globe, together with innovators.

#buildtogether #jointhecube

Jan Boehler’s Story

Jan serves as the co-founder and Chairman of the Board at xcube.bio. With a history spanning over 15 years, he has been involved in M&A, organizational strategy, integration, and financial oversight across diverse industries, including Biotech.
Having had the opportunity to collaborate with respected organizations such as Deloitte, RUAG International, SAP and in his current role as VP M&A Integration and Separation Management Office at Thomson Reuters, Jan has contributed to shaping organizational paths and guiding them towards steady growth. He values the collective effort behind nurturing new ventures and believes in the collaborative spirit when integrating companies into larger corporate families.
Throughout his journey, Jan has been part of teams that have facilitated noteworthy acquisitions and spin-offs in the biotech realm and other sectors. His experience in healthcare and technological industries, have equipped him to contribute thoughtfully to the evolution of biopharmaceutical organizations.
With a focus on the intersection of technology and medical advancements, Jan has been dedicated to improving the delivery process of essential medicines, emphasizing the importance of teamwork and shared vision. Through his counsel, he seeks to help xcube.bio to simplify the path between biopharma innovators and patients.

#buildtogether #jointhecube

Marine Baxendell Story

Marine is the Chief Financial Officer and an investor of xcube.bio bringing a wealth of expertise gained from extensive experience within the US and EU biotech communities, supported by a solid foundation in financial management.
Notably, she played a pivotal role in pioneering personalized medicine as one of the founding members of the Biogen Digital Health unit. Prior to this, Marine spent several years at Monitor-Deloitte, advising biotech firms on commercialization strategies from both Boston, MA and London, UK offices. Her career commenced in investment banking at Goldman Sachs and Capital One.
Marine holds a Master of Science from HEC Paris and a Master in international management from the Chinese University of Hong Kong.
Driven by a passion to facilitate life-saving innovations reaching patients in the most efficient manner possible, Marine is poised to leverage her expertise in technologies and financial engineering as she embarks on her journey with xcube.bio.

#buildtogether #jointhecube

Ludo Ooms’ Story

Ludo is co-founder, board member and senior advisor to xcube.bio bringing over 30 years of experience in pharmaceutical & biotech finance, general management and entrepreneurship. He held multiple executive function at Johnson & Johnson in the US and Europe, including European CFO Janssen Europe Middle East and Africa, and co-founded Cascador Health in 2021.
Ludo brings to xcube.bio a world-class knowledge in operational finance and treasury, robust pharma commercial practice, and multiple board membership. Over his career, he assessed, participated, delivered and integrated several biopharma deals, including Johnson & Johnson’s $30b USD Actelion acquisition. He combines a 360-degree view of the pharmaceutical industry with a pragmatic and no “non-sense” mindset.
Ludo is passionate about improving patient outcomes, innovation and financing. He co-founded xcube.bio with the aim to give innovative biopharma assets a viable and rewarding path to commercialization across the globe.

#buildtogether #jointhecube

Kriti Sharrma’s story

Kriti is an investor in xcube.bio where she brings a world class vision of deep-tech and product innovation. She is currently a board member for Rightmove PLC, a FTSE 100 business, and is the Chief Product Officer, LegalTech, for Thomson Reuters. She was named in the Forbes 30 Under 30 list for advancements in AI and is a Google Anita Borg Scholar.
Kriti has deep passion for ethical AI, pioneering techniques to tackle social challenges, such as healthcare delivery through AI for Good. She was awarded the Prime Minister’s Points of Light award for creating ‘AI for Good’. Her work is frequently featured in global media such as the Financial Times, Harvard Business Review, BBC. She was appointed a United Nations Young Leader in 2018. Her TED talk on AI has led to a global movement towards applying AI for social good.
As xcube.bio’s investor, Kriti is a steadfast believer in ethical AI for biopharma, to deliver better and quicker healthcare solutions to patients.

#buildtogether #jointhecube